Abstract
Neurosyphilis is an infection caused by the bacterium Treponema pallidum subspecies pallidum (T. pallidum). It can occur at any time during the course of syphilis, and enters the body through the cousin-infection derived from primary chancre syphilitic, most patients generate an effective immune response that prevents the development of complications of infection in the CNS, however, some patients do not effectively eliminate the invasion to the CNS, thus developing asymptomatic or symptomatic neurosyphilis. It has been divided into early and late stages. The early stages include asymptomatic meningitis, symptomatic meningitis, gum syphilis, and meningovascular syphilis, while the late stages include paralytic dementia and tabes dorsalis. Since, to date, there is no highly specific and sensitive test, the diagnosis is based on clinical suspicion, serological studies, and the presence of CSF abnormalities. The importance in its diagnosis derives in avoiding the complications and potentially serious sequelae of the evolution of the disease without treatment. The management of neurosyphilis is limited to receiving penicillin therapy. Follow-up includes follow-up of serological and CSF tests in specific patients. Patients with co-infection with HIV may have an earlier development of neurological characteristics than people without the infection, as well as a high probability of an incomplete response to treatment. We present the case of a man in his fifth decade of life with human immunodeficiency virus (HIV) infection without antiretroviral therapy, with subacute fever, compromise of higher mental functions, Argyll Robertson pupil, myoclonus, and ataxic march. The treponemal tests developed in the hospitalization were positive, an abnormal CSF was obtained due to the presence of hyperprotein spinal cord, as well as anti-treponema pallidum antibodies in 6.56 positive in CSF, the diagnosis of tabes dorsalis was considered, for which treatment with penicillin was started intravenous crystalline 24 million international units (IU) day, for 14 days, with favorable clinical evolution. This article reviews the definition of aetiology, pathogenesis, clinical manifestations, diagnosis and treatment of neurosyphilis, with special attention to the presence of neurosyphilis with co-infection with HIV and its relevance to clinicians in the field of neurology.
References
Berger JR, Dean D. Neurosyphilis. En: Handbook of Clinical Neurology [Internet]. Elsevier; 2014 [citado 13 de diciembre de 2020]. p. 1461-72. Disponible en: Disponible en: https://linkinghub.elsevier.com/retrieve/pii/B9780702040887000985
Clement ME, Okeke NL, Hicks CB. Treatment of Syphilis: A Systematic Review. JAMA. 2014;312(18):1905.
World Health Organization. GLOBAL HEALTH SECTOR STRATEGY ON SEXUALLY TRANSMITTED INFECTIONS 2016-2021. 2016;1-64.
Workowski KA, Berman SM. Centers for Disease Control and Prevention Sexually Transmitted Disease Treatment Guidelines. Clinical Infectious Diseases. 2011;53(suppl_3):S59-63.
Yanhua W, Haishan S, Le H, Xiaomei Z, Xinru C, Ling L, et al. Clinical and neuropsychological characteristics of general paresis misdiagnosed as primary psychiatric disease. BMC Psychiatry. 2016;16(1):230.
Bhai S, Lyons JL. Neurosyphilis Update: Atypical is the New Typical. Curr Infect Dis Rep. 2015;17(5):20.
Gonzalez H, Koralnik IJ, Marra CM. Neurosyphilis. Semin Neurol. 2019;39(04):448-55.
Edmondson DG, Hu B, Norris SJ. Long-Term In Vitro Culture of the Syphilis Spirochete Treponema pallidum subsp. pallidum. mBio. 2018;9(3):e01153-18, /mbio/9/3/mBio.01153-18.atom.
Thomas DD, Navab M, Haake DA, Fogelman AM, Miller JN, Lovett MA. Treponema pallidum invades intercellular junctions of endothelial cell monolayers. Proceedings of the National Academy of Sciences. 1988;85(10):3608-12.
Lukehart SA. Invasion of the Central Nervous System by Treponema pallidum: Implications for Diagnosis and Treatment. Ann Intern Med. 1988;109(11):855.
Baker-Zander SA, Lukehart SA. Macrophage-Mediated Killing of Opsonized Treponema pallidum. Journal of Infectious Diseases. 1992;165(1):69-74.
Marra CM, Tantalo LC, Sahi SK, Dunaway SB, Lukehart SA. Reduced Treponema pallidum -Specific Opsonic Antibody Activity in HIV-Infected Patients With Syphilis. J Infect Dis. 2016;213(8):1348-54.
Braxton J, Davis D, Emerson B, Flagg E, Grey J, Grier L, et al. Sexually Transmitted Disease Surveillance 2017. 2017;1-142.
Daey Ouwens IM, Koedijk FDH, Fiolet ATL, van Veen MG, van den Wijngaard KC, Verhoeven WMA, et al. Neurosyphilis in the mixed urban-rural community of the Netherlands. Acta Neuropsychiatr. 2014;26(3):186-92.
Conde-Sendín MÁ, Amela-Peris R, Aladro-Benito Y, Maroto AA-M. Current Clinical Spectrum of Neurosyphilis in Immunocompetent Patients. Eur Neurol. 2004;52(1):29-35.
de Voux A, Kidd S, Torrone EA. Reported Cases of Neurosyphilis Among Early Syphilis Cases-United States, 2009 to 2015: Sexually Transmitted Diseases. 2018;45(1):39-41.
Galindo J, Mier JF, Miranda CA, Rivas JC. Neurosífilis: un problema antiguo que no pierde actualidad. Revista Colombiana de Psiquiatría. 2017;46:69-76.
Ropper AH. Neurosyphilis. Longo DL, editor. N Engl J Med. 2019;381(14):1358-63.
Oette M, Hemker J, Feldt T, Sagir A, Best J, Haussinger D. Case Report: Acute Syphilitic Blindness in an HIV-Positive Patient. AIDS Patient Care and STDs. 2005;19(4):209-11.
Pearce JMS. Romberg and His Sign. Eur Neurol. 2005;53(4):210-3.
Kellett MW, Young GR, Fletcher NA. Paraparesis Due to Syphilitic Aortic Dissection. Neurology. 1997;48(1):221-3.
Roberts MC, Emsley RA, Jordaan GP. Screening for syphilis and neurosyphilis in acute psychiatric admissions. SAMJ. 1992;82:16-8.
Zifko U, Zier G, Schindler DWE. MRI in patients with general paresis. Neuroradiology. 1996;38:120-3.
Katz KA, Pillay A, Ahrens K, Kohn RP, Hermanstyne K, Bernstein KT, et al. Molecular Epidemiology of Syphilis-San Francisco, 2004-2007: Sexually Transmitted Diseases. 2010;660-3.
Johns D, Tierney M, Donna Felsenstein. Alteration in the natural history of neurosyphilis by concurrent infection with the human immunodeiciency virus. N Engl J Med. 1987;316(25):1569-72.
Smith JL, Byrne SF. Syphiloma/Gumma of the Optic Nerve and Human Immunodeiciency Virus Seropositivity. journal of clinical Neuro-ophthalmology. 1990;10(3):175-84.
Kwang K, Geol M, Bock J. Production and characterization of monoclonal antibodies to Treponema pallidurn. Journal of dermatological Science. 1992;26-32.
Marra CM, Sahi SK, Tantalo LC, Godornes C, Reid T, Behets F, et al. Enhanced Molecular Typing of Treponema pallidum : Geographical Distribution of Strain Types and Association with Neurosyphilis. J INFECT DIS. 2010;202(9):1380-8.
Hobbs E, Vera JH, Marks M, Barritt AW, Ridha BH, Lawrence D. Neurosyphilis in patients with HIV. Pract Neurol. 2018;18(3):211-8.
Chen C-W, Chiang H-C, Chen P-L, Hsieh PF, Lee Y-C, Chang M-H. General Paresis with Reversible Mesial Temporal T2-weighted Hyperintensity on Magnetic Resonance Image: A Case Report. 2005;14(4):5.
Frieden T, Jaffe H, Cono J, Richards C, Iademarco M. Sexually Transmitted Diseasses Treatment Guidelines. MMWR Recomm Rep. 2015;64(3):1-135.
Dowell ME, Ross PG, Musher DM, Cate TR, Baughn RE. Response of latent syphilis or neurosyphilis to ceftriaxone therapy in persons infected with human immunodeiciency virus. The American Journal of Medicine. 1992;93(5):481-8.
Kingston M, French P, Higgins S, McQuillan O, Sukthankar A, Stott C, et al. UK national guidelines on the management of syphilis 2015. Int J STD AIDS. 2016;27(6):421-46.
Janier M, Hegyi V, Dupin N, Unemo M, Tiplica GS, Potocnik M, et al. 2014 European guideline on the management of syphilis. J Eur Acad Dermatol Venereol. 2014;28(12):1581-93.
Marra CM, Boutin P, McArthur JC, Hurwitz S, Simpson G, Haslett JPA, et al. A Pilot Study Evaluating Ceftriaxone and Penicillin G as Treatment Agents for Neurosyphilis in Human Immunodeiciency Virus-Infected Individuals. Clinical Infectious Diseases. 2000;30(3):540-4.
Fathilah J, Choo M. The Jarisch-Herxheimer Reaction in Ocular Syphilis. Med J Malaysia. 2003;58(3):437-9.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.